The Impact of Molecular Testing on Treatment Choices for NSCLC
A discussion with Dr. Garon highlights patient selection for EGFR inhibitor therapy in EGFR+ NSCLC, emphasizing the critical role of biomarker testing, testing approaches, and overcoming barriers in community settings.
Robert’s Journey With EGFR+ Metastatic NSCLC
The video segment profiles a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope throughout his treatment journey.